What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His main research concerns Internal medicine, Myeloid leukemia, Oncology, Imatinib and Leukemia.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Surgery and Immunology.
His biological study spans a wide range of topics, including Survival rate, Tet methylcytosine dioxygenase 2, Bone marrow and NPM1.
His Oncology research focuses on subjects like Discontinuation, which are linked to Ruxolitinib.
His research integrates issues of Chronic myelogenous leukemia, Tyrosine kinase and Tyrosine-kinase inhibitor in his study of Imatinib.
His Leukemia research incorporates themes from Myelodysplastic syndromes, Azacitidine, Hematology and Pharmacology.
His most cited work include:
- The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (452 citations)
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies (178 citations)
- Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome. (154 citations)
What are the main themes of his work throughout his whole career to date?
Elias Jabbour mostly deals with Internal medicine, Oncology, Myeloid leukemia, Surgery and Gastroenterology.
His Dasatinib, Imatinib, Cytarabine, Leukemia and Transplantation study are his primary interests in Internal medicine.
His study in Dasatinib is interdisciplinary in nature, drawing from both Nilotinib and Imatinib mesylate.
The concepts of his Oncology study are interwoven with issues in Chemotherapy, Phases of clinical research, Immunology and Decitabine.
His research in Myeloid leukemia intersects with topics in Myeloid, Tyrosine kinase, Cancer and Bone marrow.
His work carried out in the field of Gastroenterology brings together such families of science as Vincristine, Refractory and Minimal residual disease.
He most often published in these fields:
- Internal medicine (77.26%)
- Oncology (44.05%)
- Myeloid leukemia (31.78%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (77.26%)
- Oncology (44.05%)
- Myeloid leukemia (31.78%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Myeloid leukemia, Cancer research and Leukemia.
Elias Jabbour performs multidisciplinary study on Internal medicine and In patient in his works.
His studies in Oncology integrate themes in fields like Phases of clinical research, Cytarabine, Inotuzumab ozogamicin, Ponatinib and Transplantation.
Elias Jabbour has researched Phases of clinical research in several fields, including Gastroenterology and Azacitidine.
The Myeloid leukemia study combines topics in areas such as Hematopoietic stem cell transplantation, Refractory, Tyrosine-kinase inhibitor, Bone marrow and Cohort.
The study incorporates disciplines such as Myeloid and Cancer in addition to Leukemia.
Between 2018 and 2021, his most popular works were:
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. (140 citations)
- The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia (82 citations)
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study (74 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Elias Jabbour focuses on Internal medicine, Oncology, Myeloid leukemia, Leukemia and Venetoclax.
His work is dedicated to discovering how Internal medicine, Decitabine are connected with Clinical endpoint and other disciplines.
Elias Jabbour interconnects Blinatumomab, Ponatinib, Cyclophosphamide and Phases of clinical research in the investigation of issues within Oncology.
His Myeloid leukemia study integrates concerns from other disciplines, such as Febrile neutropenia, NPM1, Cohort and Bone marrow.
His Leukemia research also works with subjects such as
- Survival rate most often made with reference to Myeloid,
- Clinical trial and related Discontinuation.
His Venetoclax research includes elements of Newly diagnosed, Intensive chemotherapy, Combination therapy and Tumor lysis syndrome.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
